Literature DB >> 17588298

Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: a pilot study.

David W Brandes1, Kim Bigley, William Hornstein, Hart Cohen, William Au, Richard Shubin.   

Abstract

OBJECTIVE: To determine the effectiveness of dose titration and choice of analgesic in reducing flu-like side effects of intramuscular interferon beta-1a (i.m. IFNbeta-1a).
METHODS: Patients were randomly assigned to receive weekly i.m. IFNbeta-1a, with or without dose titration, plus acetaminophen or ibuprofen. After 27 patients had been randomized, the original formulation of i.m. IFNbeta-1a became unavailable and the remaining patients used a pre-packaged liquid formulation, necessitating a change in protocol from initially quarter-dose to half-dose titration. Patients scored presence and intensity of muscle aches, chills, and weakness, and measured body temperature; information was recorded in diaries.
RESULTS: Forty-seven patients were enrolled; 36 completed the study. Fifteen patients received full-dose therapy plus acetaminophen, eight patients received quarter-dose titration and acetaminophen, 10 patients received quarter-dose titration and ibuprofen, eight patients received half-dose titration and acetaminophen, and six patients received half-dose titration and ibuprofen. The mean number of acetaminophen doses taken was not statistically different from the mean number of ibuprofen doses taken per patient per week in any dose-titration group over measured time intervals (p > 0.05). Symptom scores from acetaminophen and ibuprofen dose-titration groups were combined and compared with the no-titration group. The proportion of patients with a mean increase of > or = 2 from baseline in flu-like symptom score trended lower in the titrated group compared with the no-titration group at 4 hours and 12-15 hours post-injection; these differences reached statistical significance only during the first 2 weeks of treatment (p = 0.015, quarter-dose vs. no titration).
CONCLUSION: This study supports the findings of previous studies demonstrating no difference in the effectiveness of acetaminophen and ibuprofen in controlling flu-like symptoms associated with IFNbeta treatment in patients with relapsing-remitting MS. Trends in this small pilot study suggest that the combination of initial dose titration and analgesic administration is useful for the reduction of flu-like symptoms with IFNbeta-1a therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17588298     DOI: 10.1185/030079907x210741

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  6 in total

1.  Nurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis.

Authors:  Mary L Filipi; Jill Beavin; Raquel T Brillante; Kathleen Costello; Gail C Hartley; Kay Hartley; Marie Namey; Shirley O'Leary; Gina Remington
Journal:  Int J MS Care       Date:  2014

2.  Injectable multiple sclerosis medications: a patient survey of factors associated with injection-site reactions.

Authors:  Thomas M Stewart; Zung Vu Tran
Journal:  Int J MS Care       Date:  2012

3.  Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a: Obtaining Recommendations Using the Delphi Technique.

Authors:  June Halper; Diego Centonze; Scott D Newsome; DeRen Huang; Christopher Robertson; Xiaojun You; Guido Sabatella; Vladimir Evilevitch; Leslie Leahy
Journal:  Int J MS Care       Date:  2016 Jul-Aug

4.  Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study.

Authors:  Doriana Landi; Maria Albanese; Fabio Buttari; Fabrizia Monteleone; Laura Boffa; Silvia Rossi; Caterina Motta; Elisa Puma; Diego Centonze
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.240

5.  Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results.

Authors:  Robert T Naismith; Barry Hendin; Sibyl Wray; DeRen Huang; Fiorenza Gaudenzi; Qunming Dong; Bjørn Sperling; Monica Mann; Brian Werneburg
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-01-30

6.  Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.

Authors:  Diego Bertoli; Federico Serana; Alessandra Sottini; Cinzia Cordioli; Davide Maimone; Maria Pia Amato; Diego Centonze; Ciro Florio; Elisa Puma; Ruggero Capra; Luisa Imberti
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.